GE HealthCare Technologies Inc. Files Definitive Proxy Statement

Ticker: GEHC · Form: DEF 14A · Filed: Apr 4, 2024 · CIK: 1932393

Ge Healthcare Technologies Inc. DEF 14A Filing Summary
FieldDetail
CompanyGe Healthcare Technologies Inc. (GEHC)
Form TypeDEF 14A
Filed DateApr 4, 2024
Risk Level
Pages14
Reading Time17 min
Key Dollar Amounts$19.6 billion, $100 billion
Sentimentneutral

Sentiment: neutral

Topics: Proxy Statement, DEF 14A, GE HealthCare, Annual Meeting, Executive Compensation

TL;DR

<b>GE HealthCare Technologies Inc. has filed its Definitive Proxy Statement for the 2024 Annual Meeting of Stockholders.</b>

AI Summary

GE HealthCare Technologies Inc. (GEHC) filed a Proxy Statement (DEF 14A) with the SEC on April 4, 2024. GE HealthCare Technologies Inc. filed a Definitive Proxy Statement (DEF 14A) on April 4, 2024. The filing covers the period ending May 21, 2024. The company's principal executive offices are located at 500 West Monroe Street, Chicago, IL 60661. The filing includes information related to equity awards, pension value changes, and stock awards for both PEO and Non-PEO members. The company was formerly known as GE Healthcare Holding LLC, with a name change date of June 3, 2022.

Why It Matters

For investors and stakeholders tracking GE HealthCare Technologies Inc., this filing contains several important signals. This filing provides crucial details regarding executive compensation, stock awards, and other financial matters that are important for shareholders to understand before voting. Shareholders can review this document to make informed decisions regarding company governance and proposals presented at the upcoming annual meeting.

Risk Assessment

Risk Level: — GE HealthCare Technologies Inc. shows moderate risk based on this filing. The filing is a routine proxy statement (DEF 14A) and does not contain new material financial information or significant operational updates, indicating a standard disclosure process.

Analyst Insight

Shareholders should review the proxy statement to understand executive compensation, voting matters, and company governance before the 2024 Annual Meeting.

Key Numbers

  • 2024-04-04 — Filing Date (DEF 14A Filing Date)
  • 2024-05-21 — Reporting Period End (Conformed Period of Report)
  • 2023-12-31 — Fiscal Year End (Company Fiscal Year End)

Key Players & Entities

  • GE HealthCare Technologies Inc. (company) — Registrant
  • 500 West Monroe Street, Chicago, Illinois 60661 (location) — Business Address
  • GE Healthcare Holding LLC (company) — Former Company Name
  • 2024 (date) — Annual Meeting Year

FAQ

When did GE HealthCare Technologies Inc. file this DEF 14A?

GE HealthCare Technologies Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 4, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by GE HealthCare Technologies Inc. (GEHC).

Where can I read the original DEF 14A filing from GE HealthCare Technologies Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by GE HealthCare Technologies Inc..

What are the key takeaways from GE HealthCare Technologies Inc.'s DEF 14A?

GE HealthCare Technologies Inc. filed this DEF 14A on April 4, 2024. Key takeaways: GE HealthCare Technologies Inc. filed a Definitive Proxy Statement (DEF 14A) on April 4, 2024.. The filing covers the period ending May 21, 2024.. The company's principal executive offices are located at 500 West Monroe Street, Chicago, IL 60661..

Is GE HealthCare Technologies Inc. a risky investment based on this filing?

Based on this DEF 14A, GE HealthCare Technologies Inc. presents a moderate-risk profile. The filing is a routine proxy statement (DEF 14A) and does not contain new material financial information or significant operational updates, indicating a standard disclosure process.

What should investors do after reading GE HealthCare Technologies Inc.'s DEF 14A?

Shareholders should review the proxy statement to understand executive compensation, voting matters, and company governance before the 2024 Annual Meeting. The overall sentiment from this filing is neutral.

How does GE HealthCare Technologies Inc. compare to its industry peers?

GE HealthCare Technologies Inc. operates in the healthcare technology sector, providing medical imaging, ultrasound, patient care solutions, and pharmaceutical diagnostics.

Are there regulatory concerns for GE HealthCare Technologies Inc.?

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

Industry Context

GE HealthCare Technologies Inc. operates in the healthcare technology sector, providing medical imaging, ultrasound, patient care solutions, and pharmaceutical diagnostics.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Section 14(a), which governs the solicitation of proxies.

What Investors Should Do

  1. Review the proxy statement for details on executive compensation and any proposed resolutions.
  2. Understand the voting procedures and deadlines for the 2024 Annual Meeting.
  3. Assess the company's governance practices as outlined in the filing.

Key Dates

  • 2024-04-04: Filing of Definitive Proxy Statement — Provides official notice and details for the upcoming 2024 Annual Meeting of Stockholders.

Year-Over-Year Comparison

This is the initial filing of the 2024 Definitive Proxy Statement, following the company's previous filings.

Filing Stats: 4,338 words · 17 min read · ~14 pages · Grade level 15.5 · Accepted 2024-04-04 07:06:26

Key Financial Figures

  • $19.6 billion — is, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 coll
  • $100 billion — otal gross debt reduction was more than $100 billion through 2023. He has championed lean, b

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This proxy statement contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as "will," "expect," "may," "would," "could," "plan," "believe," "anticipate," "intend," "estimate," "potential," "position," "forecast," "target," "guidance," "outlook," and similar expressions. These forward-looking statements may include, but are not limited to, statements about our business operations; our strategy, including with respect to our sustainability initiatives and governance and compensation practices and policies; our agreements with General Electric Company ("GE"); and financial information. Please see our risk factors, as they may be amended from time to time, set forth in our filings with the U.S. Securities and Exchange Commission (the "SEC"), including our most recently filed Annual Report on Form 10-K (the "2023 Form 10-K"). There may be other factors not presently known to us or which we currently consider to be immaterial that could cause our actual results to differ materially from those projected in any forward-looking statements we make. In addition, historical, current, and forward-looking environmental and social-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future. We caution you that these statements are not guarantees of future performance, nor promises that goals or targets will be met, and are subject to numerous and evolving risks and uncertainties that we may not be able to predict or assess. We do not undertake any obligation to update or revise our forward-looking statements except as required by applicable law or regulation. 2 GE HEALTHCARE 2024 PROXY STATEMENT Proxy Statement Summary This section summarizes and highlights certain information contained in this proxy statement but does not con

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.